Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context

Inclusion Criteria: Participants are eligible to be included in the study only if all the following criteria apply: * Patients (male or female) 18 years of age or older at age inclusion * Patients with histologically or cytologically confirmed diagnosis of locally advanced or metastatic (TNM 8th classification) ALK-positive NSCLC (IHC 3+/FISH positive/transcriptomic method) * Complete radiological evaluation has to be performed before the start of lorlatinib by contrast enhanced CT-scan of thorax and upper abdomen and brain MRI, as per routine care * Patients with ECOG performance status grade 0, 1, or 2 Exclusion Criteria: Participants are excluded from the study if any of the following criteria Apply * Evidence of active malignancy within the last 2 years prior to inclusion (other than NSCLC, non-melanoma skin cancer, cervical in situ cancer, papillary thyroid cancer, lobular carcinoma in situ/ductal carcinoma in situ (LCIS/DCIS) of the breast, or localized prostate cancer). * Patients who have previously received adjuvant ALK TKI therapy (unless metastatic relapse occurs more than one year after completion of adjuvant therapy). * Patients who have previously received systemic NSCLC therapy in metastatic condition. * Patients using any of the following food or drugs within 12 days prior to the first dose of lorlatinib: * known strong CYP3A inhibitors * known strong CYP3A inducers * known P gp substrates with a narrow therapeutic index * Patients with any medical o…